NSAIDs in Pericarditis
Aspirin or ibuprofen at high doses combined with colchicine is the first-line treatment for acute pericarditis, with aspirin 750-1000 mg every 8 hours or ibuprofen 600 mg every 8 hours for 1-2 weeks, tapered gradually based on symptom resolution and CRP normalization. 1
Drug Choice
The 2015 ESC Guidelines establish aspirin and NSAIDs as Class I, Level A recommendations for acute pericarditis 1. Your choice between agents should be guided by:
- Aspirin: Preferred when the patient already requires antiplatelet therapy for cardiovascular disease
- Ibuprofen: Generally preferred for most other patients due to better tolerability and fewer gastrointestinal side effects
- Indomethacin: Reserved for refractory cases (25-50 mg every 8 hours), though it carries higher risk of headache and dizziness 1
Recent data from Denmark (2024) provides reassuring evidence that high-dose ibuprofen for pericarditis does not increase cardiovascular risks—in fact, it was associated with lower MACE rates compared to non-use (HR 0.69,95% CI: 0.54-0.89) 2.
Dosing Regimen
Acute Pericarditis (First Episode)
Initial Treatment:
- Aspirin: 750-1000 mg every 8 hours (total 2.25-3 g/day) 1
- Ibuprofen: 600 mg every 8 hours (total 1800 mg/day) 1
- Duration: Continue full doses for 1-2 weeks or until symptoms resolve and CRP normalizes 1
Tapering:
- Aspirin: Decrease by 250-500 mg every 1-2 weeks 1
- Ibuprofen: Decrease by 200-400 mg every 1-2 weeks 1
- Tapering should only occur when the patient is asymptomatic and CRP is normal 1
Recurrent Pericarditis
For recurrences, the same NSAID regimen applies, but with potentially longer treatment duration (weeks to months) and slower tapering for resistant cases 1. The guidelines emphasize that aspirin doses can range from 1.5-4 g/day for recurrent cases 1.
Mandatory Adjunctive Therapy
Colchicine is non-negotiable (Class I, Level A recommendation) 1:
- Dosing: 0.5 mg twice daily if ≥70 kg; 0.5 mg once daily if <70 kg 1
- Duration: Minimum 3 months for first episode; at least 6 months for recurrences 1
- Effect: Reduces recurrence rates from 37.5% to 16.7% (absolute risk reduction 20.8%) 3
Gastroprotection is mandatory with all NSAID therapy 1. Use proton pump inhibitors throughout the treatment course.
Contraindications and When NOT to Use NSAIDs
NSAIDs should be avoided in:
- True allergy to NSAIDs
- Recent peptic ulcer or active gastrointestinal bleeding
- Oral anticoagulation with high bleeding risk 1
- Severe renal dysfunction
- Severe heart failure
In these cases, proceed directly to low-dose corticosteroids (prednisone 0.2-0.5 mg/kg/day, NOT 1.0 mg/kg/day) after excluding infectious causes 1.
Critical Pitfalls to Avoid
Never use corticosteroids as first-line therapy (Class III recommendation) 1. They increase recurrence rates up to 50% and promote chronic disease 1
Do not taper NSAIDs too rapidly—this triggers inflammatory rebound. Each dose reduction should occur only when symptoms are absent and CRP is normal 1
Do not stop colchicine prematurely. The 3-month minimum is essential; stopping earlier increases recurrence risk 1
Monitor CRP to guide treatment duration, not just symptoms. Treatment should continue until CRP normalizes 1
Restrict exercise until symptoms resolve, CRP normalizes, and ECG/echo normalize—minimum 3 months for athletes 1
Treatment Algorithm
Step 1: Start high-dose NSAID (aspirin or ibuprofen) + colchicine + gastroprotection
Step 2: Continue full doses for 1-2 weeks until symptom resolution and CRP normalization
Step 3: Begin gradual taper (aspirin by 250-500 mg or ibuprofen by 200-400 mg every 1-2 weeks)
Step 4: Continue colchicine for full 3 months (6+ months for recurrences)
Step 5: If inadequate response after 4-6 weeks, consider adding low-dose corticosteroids (0.2-0.5 mg/kg/day prednisone) as triple therapy, NOT as replacement 1
Step 6: For multiple recurrences refractory to NSAIDs + colchicine + low-dose steroids, consider IL-1 blockers (anakinra, rilonacept) before resorting to pericardiectomy 1, 4
The evidence strongly supports this approach, with the ESC guidelines providing the most comprehensive and authoritative framework [1-1], reinforced by recent real-world data confirming the safety profile of high-dose ibuprofen 2.